GP CCE Cases · musculoskeletal-presentations
Gout — recurrent flares, no ULT — CCE clinical encounter
CCE-style clinical encounter: a 54-year-old hotel manager with four gout flares in two years, tophi on the ear, uncontrolled hypertension on a thiazide and heavy beer intake. The candidate must treat today's flare, introduce urate-lowering therapy with prophylaxis, titrate-to-target plan, lifestyle framing and comorbidity review.
On this page
Study tools
Target exams
RACGP CCEFRACGP oralsCFPC SOOs
Prompt
A 54-year-old hotel manager attends for 'the strong painkiller that worked last time'. His right ankle is red, hot and swollen; he is limping. He has had about four severe attacks in two years. You notice a small firm nodule on his left ear helix. Medications: chlorthalidone 25 mg for hypertension (BP today 148/92). He drinks three to six beers a night ('it's my job'), BMI 31. eGFR 62. He has never heard of urate-lowering therapy.
Objectives
- Treat today's flare promptly with a regimen suited to his profile. [1] [3]
- Diagnose chronic gout credibly: tophi plus recurrent flares meet ULT indications. [20] [1]
- Introduce allopurinol with target-driven titration AND prophylactic cover — and explain why both matter. [7] [6]
- Deliver lifestyle advice with numbers he will remember (beer first). [12]
- Review the thiazide and metabolic comorbidities without derailing the consultation. [19]
References10ShowHide
- [1]FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol, 2020.PMID 32390306
- [3]Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum, 2010.PMID 20131255
- [6]Wortmann RL, Macdonald PA, Hunt B, Jackson RL Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther, 2010.PMID 21353107
- [7]Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum, 2014.PMID 24560169
- [10]Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med, 2004.PMID 15014182
- [11]Choi HK, Curhan G Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ, 2008.PMID 18244959
- [12]Lyu JQ, Miao MY, Wang JM, Qian YW, Han WW, et al. Consumption of Total and Specific Alcoholic Beverages and Long-Term Risk of Gout Among Men and Women. JAMA Netw Open, 2024.PMID 39196557
- [13]GBD 2021 Gout Collaborators Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol, 2024.PMID 38996590
- [19]Afinogenova Y, Danve A, Neogi T Update on gout management: what is old and what is new. Curr Opin Rheumatol, 2022.PMID 34907116
- [20]Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 2015.PMID 26359487